AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength

  • AstraZeneca Plc AZN has reported Q3 core EPS of $1.67, up 55% Y/Y (+70 constant currency), beating the consensus of $0.72.
  • The company clocked Q3 sales of $10.98 billion, +11% (+19% CC), beating the consensus of $10.91 billion.
  • Sales of AstraZeneca's key cancer medicines — Tagrisso and Imfinzi — helped the company's revenue beat, with sales of its broader oncology portfolio rising 24%.
  • Tagrisso generated nearly $1.4 billion, and Imfinzi brought in $737 million in the quarter. 
  • Related: FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids.
  • Sales of its Covid-19 vaccine Vaxzevria slumped 83% Y/Y to $173 million compared to $455 million in Q2 FY22.
  • AstraZeneca has decided not to submit an FDA marketing application for Vaxzevria. It will continue to focus its efforts on ensuring the availability of Vaxzevria elsewhere, including submissions for its use as a booster.
  • Earlier in the year, AstraZeneca said it would consider not submitting its COVID-19 vaccine for approval in the U.S. if the regulatory process takes too long.
  • Guidance: AstraZeneca expects its full-year adjusted profit per share to increase by a "high twenties to low thirties percentage." Previously, it had forecast a 2022 gain in the "mid-to-high twenties percentage."
  • AstraZeneca on Thursday said its anticipated 2022 revenue growth would be impacted by a currency headwind of a "mid-single-digit percentage."
  • Core earnings per share for the year will also be negatively affected by a "mid-to-high single-digit percentage," it added.
  • Price Action: AZN shares are up 4.75% at $63.95 premarket on the last check Thursday.
  • Photo by Paul McManus from Pixabay
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareFDAPre-Market OutlookMoversTrading IdeasGeneralBriefswhy it's moving